ATORX Stock Overview
A research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Alligator Bioscience AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.58 |
| 52 Week High | SEK 1.57 |
| 52 Week Low | SEK 0.40 |
| Beta | 1.48 |
| 11 Month Change | -54.12% |
| 3 Month Change | -53.38% |
| 1 Year Change | 40.70% |
| 33 Year Change | -74.61% |
| 5 Year Change | -95.07% |
| Change since IPO | -98.48% |
Recent News & Updates
Recent updates
Will Alligator Bioscience (STO:ATORX) Spend Its Cash Wisely?
Dec 01
We're Keeping An Eye On Alligator Bioscience's (STO:ATORX) Cash Burn Rate
Dec 21Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jul 30Is Alligator Bioscience (STO:ATORX) In A Good Position To Invest In Growth?
Jan 06Here's Why We're Watching Alligator Bioscience's (STO:ATORX) Cash Burn Situation
Aug 18Shareholder Returns
| ATORX | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -14.5% | -5.6% | -3.6% |
| 1Y | 40.7% | 17.3% | 12.3% |
Return vs Industry: ATORX exceeded the Swedish Biotechs industry which returned 17.3% over the past year.
Return vs Market: ATORX exceeded the Swedish Market which returned 12.3% over the past year.
Price Volatility
| ATORX volatility | |
|---|---|
| ATORX Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ATORX's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ATORX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 47 | Søren Bregenholt | www.alligatorbioscience.se |
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Sweden. The company’s product portfolio includes Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage. It also offers ALG
Alligator Bioscience AB (publ) Fundamentals Summary
| ATORX fundamental statistics | |
|---|---|
| Market cap | SEK 465.44m |
| Earnings (TTM) | -SEK 248.30m |
| Revenue (TTM) | SEK 27.77m |
15.8x
P/S Ratio-1.8x
P/E RatioIs ATORX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATORX income statement (TTM) | |
|---|---|
| Revenue | SEK 27.77m |
| Cost of Revenue | SEK 182.11m |
| Gross Profit | -SEK 154.33m |
| Other Expenses | SEK 93.97m |
| Earnings | -SEK 248.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.33 |
| Gross Margin | -555.68% |
| Net Profit Margin | -894.02% |
| Debt/Equity Ratio | 0% |
How did ATORX perform over the long term?
See historical performance and comparison